- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05152927
Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, single-blinded, randomized study comparing the use of PTeye during parathyroidectomy to usual standard practice.
PRIMARY OBJECTIVES:
I. Assess the impact of PTeye on intra-operative identification of parathyroid tissues.
II. Assess the impact of PTeye on improving efficiency of parathyroid surgeries.
III. Assess the impact of PTeye on minimizing risk of post-surgical complications.
Participants will be randomized to either the experimental or control arm.
The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscles, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements. The subsequent step would involve touching the target tissue in the neck with the fiber optic probe, following which the PTeye will indicate to the surgeon if the tissue is likely parathyroid or not.
For patients assigned to the control arm, the surgeon will not use the PTeye and will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
Participants will be follow-ed up for up to 6 months after surgery.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Brandon Yap
- Phone Number: 877-827-3222
- Email: Brandon.Yap@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of California, San Francisco
-
Contact:
- Brandon Yap
- Email: Brandon.Yap@ucsf.edu
-
Principal Investigator:
- Quan-Yang Duh, MD, FACS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All adults >=18 years old) patients with primary hyperparathyroidism who will be undergoing parathyroid surgery
- All adult (>=18 years old) patients with persistent primary hyperparathyroidism after having undergone a failed prior parathyroid surgery who will be undergoing repeat parathyroid surgery
Exclusion Criteria:
- Children and minors
- Pregnant women
- Patients with concurrent parathyroid and thyroid disease that require total thyroidectomy
- Patients with secondary or tertiary hyperparathyroidism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Parathyroid Eye (PTeye)
For patients assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Intraoperative Tool
Other Names:
|
No Intervention: Usual Standard of Care
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median number of frozen sections (or PTH aspirate) sent for analysis
Time Frame: 1 day
|
Number of frozen sections (or PTH aspirate) sent for analysis during the Parathyroidectomy (PTx) procedure to confirm potential parathyroid tissue
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with persistent hyperparathyroidism (Immediate)
Time Frame: 1 day
|
Failure of intra-operative parathyroid hormone (PTH) to normalize (defined as failure of PTH to drop > 50% of its baseline value at final intra-operative PTH assay and/or failure of PTH to drop < 65 pg/ml or 6.9 pmol/L).
Participants will be categorized as having persistent hyperparathyroidism (Immediate) Yes or No.
|
1 day
|
Number of participants with persistent hyperparathyroidism or hypercalcemia (transient)
Time Frame: 5-14 days after PTx procedure
|
Elevated blood calcium levels (total blood calcium level > 10.5 mg/dL or 2.6 mmol/L) with/without elevated parathyroid hormone (PTH) (serum intact PTH > 65 pg/ml or 6.9 pmol/L) at first postoperative visit.
Participants will be categorized as having persistent hyperparathyroidism or hypercalcemia (transient) Yes or No.
|
5-14 days after PTx procedure
|
Number of participants persistent hyperparathyroidism or hypercalcemia (failed parathyroidectomy)
Time Frame: Up to 6 months after PTx procedure
|
If blood calcium with/without parathyroid hormone (PTH) has not normalized at 1st post-operative visit, calcium and/or PTH is subsequently measured as necessary.
Patient is defined to have a failed parathyroidectomy if hypercalcemia/hyperparathyroidism (defined as total blood calcium level > 10.5 mg/dL or 2.6 mmol/L, with/without elevated serum intact PTH > 65 pg/ml or 6.9 pmol/L) persists at or after the 6th postoperative month.
Participants will be categorized has having persistent hyperparathyroidism or hypercalcemia (failed parathyroidectomy), Yes or No.
|
Up to 6 months after PTx procedure
|
Number of parathyroid glands (PG) identified
Time Frame: 1 day
|
Overall number of parathyroid glands identified (Experimental Group: Glands identified with naked eye + NIRAF;Control Group: Glands identified with naked eye)
|
1 day
|
Median number of parathyroid glands identified with NIRAF
Time Frame: 1 day
|
Median number of parathyroid glands identified with NIRAF, which was not seen with surgeon's naked eye
|
1 day
|
Median number of diseased parathyroid glands identified versus preoperatively localized glands
Time Frame: 1 day
|
Median number of diseased parathyroid glands identified intra-operatively versus glands localized preoperatively using sestamibi, Computerized tomography (CT) or ultrasound
|
1 day
|
Median number of intra-operative parathyroid hormone (PTH) assays sent
Time Frame: 1 day
|
Median number of intra-operative parathyroid hormone assays per person sent during the procedure to the lab
|
1 day
|
Median duration taken to identify first parathyroid gland
Time Frame: 1 day
|
Median duration in minutes taken to identify 1st parathyroid gland in PTx procedure - timed from skin incision to finding PG
|
1 day
|
Median duration taken to identify last parathyroid gland
Time Frame: 1 day
|
Median duration taken to identify last parathyroid gland in PTx procedure - timed from skin incision to finding the last PG
|
1 day
|
Median duration of parathyroidectomy (PTx) procedure
Time Frame: 1 day
|
Median duration of PTx procedure - timed from skin incision until the surgeon notifies the anesthesia team to awaken the patient in minutes
|
1 day
|
Median duration for intraoperative parathyroid hormone (PTH) to normalize
Time Frame: 1 day
|
Median time in minutes taken for PTH to attain cure criteria or normalize - timed from skin incision until the PTH levels drops > 50% of its baseline value and/or PTH drops < 65 pg/ml or 6.9 pmol/L
|
1 day
|
Median number of nights spent in the hospital after parathyroidectomy
Time Frame: 0-72 hours after PTx procedure
|
Number of nights spent for postoperative recovery in the hospital after the surgical procedure
|
0-72 hours after PTx procedure
|
Median number of 'false positive' tissues excised by surgeon
Time Frame: Up to 10 days after PTx procedure
|
Median number of tissues per person that were excised by surgeon assumed to be parathyroid tissue, but is later validated as nonparathyroid tissue (false positive) by histology
|
Up to 10 days after PTx procedure
|
Number of participants with reported doctor visits/emergency department visits or hospital admissions
Time Frame: Up to 6 months after PTx procedure
|
Number of doctor visits/emergency department visits or hospital admissions due to persistent hypercalcemia and/or associated symptoms after parathyroidectomy procedure will be categorized as binary (yes or no)
|
Up to 6 months after PTx procedure
|
Number of participants who have had repeat parathyroidectomy (PTx) procedure
Time Frame: From 6 - 12 months after PTx procedure
|
Number of patients with repeat PTx procedure performed after the current procedure will be categorized as binary (yes or no)
|
From 6 - 12 months after PTx procedure
|
Collaborators and Investigators
Investigators
- Principal Investigator: Quan-Yang Duh, MD, FACS, University of California, San Francisco
Publications and helpful links
General Publications
- McWade MA, Paras C, White LM, Phay JE, Mahadevan-Jansen A, Broome JT. A novel optical approach to intraoperative detection of parathyroid glands. Surgery. 2013 Dec;154(6):1371-7; discussion 1377. doi: 10.1016/j.surg.2013.06.046.
- Thomas G, Solorzano CC, Baregamian N, Mannoh EA, Gautam R, Irlmeier RT, Ye F, Nelson JA, Long SE, Gauger PG, Magner A, Metcalf T, Shirley LA, Phay JE, Mahadevan-Jansen A. Comparing intraoperative parathyroid identification based on surgeon experience versus near infrared autofluorescence detection - A surgeon-blinded multi-centric study. Am J Surg. 2021 Nov;222(5):944-951. doi: 10.1016/j.amjsurg.2021.05.001. Epub 2021 May 13.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Endocrine System Diseases
- Head and Neck Neoplasms
- Calcium Metabolism Disorders
- Water-Electrolyte Imbalance
- Neoplasms
- Hyperparathyroidism
- Hyperparathyroidism, Primary
- Adenoma
- Neoplasms, Glandular and Epithelial
- Endocrine Gland Neoplasms
- Parathyroid Neoplasms
- Parathyroid Diseases
- Hypercalcemia
- Physiological Effects of Drugs
- Calcium-Regulating Hormones and Agents
- Parathyroid Hormone
Other Study ID Numbers
- 21208
- 5R01CA212147-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms, Glandular and Epithelial
-
Catalysis SLRecruitingNeoplasms | Carcinoma | Neoplasia; Intraepithelial, Cervix | Glandular Neoplasms | Epithelial NeoplasmCuba
-
Providence Health & ServicesCelldex TherapeuticsEnrolling by invitationMalignant Epithelial NeoplasmsUnited States
-
Providence Health & ServicesActive, not recruitingMalignant Epithelial NeoplasmsUnited States
-
Genentech, Inc.CompletedEpithelial Tumors, MalignantSpain, United States
-
Synermore Biologics Co., Ltd.Synermore Biologics USA LimitedActive, not recruitingSolid Tumor | Epithelial CarcinomaUnited States
-
Vall d'Hebron Institute of OncologyBanc de Sang i TeixitsRecruiting
-
Institut CurieRecruiting
-
Sesen Bio, Inc.TerminatedNeoplasms, Glandular and EpithelialRussian Federation, Georgia
-
Akamis BioMerck Sharp & Dohme LLCRecruitingStudy of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) (FORTIFY)Metastatic Cancer | Epithelial TumorUnited States, United Kingdom
-
Oslo University HospitalCompleted
Clinical Trials on Parathyroid Eye (PTeye)
-
University of MichiganNational Cancer Institute (NCI); Vanderbilt UniversityRecruitingNeoplasms | Neoplasms by Site | Endocrine System Diseases | Endocrine Gland Neoplasms | Head and Neck Neoplasms | Parathyroid Diseases | Thyroid Diseases | Thyroid Neoplasms | HypoparathyroidismUnited States
-
University of MichiganNational Cancer Institute (NCI); Vanderbilt UniversityRecruitingPrimary Hyperparathyroidism | Parathyroid Neoplasms | Hypercalcemia | Parathyroid Adenoma | Parathyroid CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Active, not recruitingPrimary Hyperparathyroidism | Parathyroid Neoplasms | Hypercalcemia | Parathyroid Adenoma | Parathyroid Cancer | Parathyroid HyperplasiaUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedThyroid Neoplasms | Thyroid Cancer | Postoperative HypoparathyroidismUnited States
-
Tongji HospitalUnknownParathyroid Autologous TransplantationChina
-
HaEmek Medical Center, IsraelWithdrawnHypercalcemia | Parathyroid AdenomaIsrael
-
University Hospital, GenevaGeneva University, School of medicineCompletedParathyroid Function Low Adverse EventSwitzerland
-
Enzyvant Therapeutics GmBHNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedDiGeorge Syndrome | DiGeorge Anomaly | Complete DiGeorge Anomaly | Complete DiGeorge SyndromeUnited States
-
University of PittsburghNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedHyperparathyroidism | Osteoporosis | Humoral Hypercalcemia of MalignancyUnited States
-
University of PittsburghNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed